BIOCRYST PHARMACEUTICALS INC (BCRX) 10.58 -0.2 (-1.86%)
10.58 -0.2 (-1.86%)
US09058V1035 - Common Stock - After market: 10.74 +0.16 (+1.51%)
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first...
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...
BCRX stock drops as sales for hereditary angioedema therapy lag forecasts (NASDAQ:BCRX)
BioCryst Pharmaceuticals (BCRX) fell ~12% on Monday after announcing lower-than-expected sales for the company's hereditary angioedema therapy Orladeyo. Read the full story here.
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in...
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
TSLA Stock Price Prediction: What to Know as Analysts Slash Tesla Price Targets
Tesla (TSLA) stock is in the news as price predictions continue to be a hot topic among traders after Elon Musk's Twitter purchase.
Why Is Getaround (GETR) Stock Up 6% Today?
Getaround (GETR) stock is on the move Thursday with heavy trading despite a lack of recent news concerning the car-sharing service.
BCRX Stock Sinks as BioCryst Discontinues Drug Development
BioCryst Pharmaceuticals (BCRX) stock is falling on Thursday after revealing it's no longer developing BCX9930 for competitive reasons.
BCRX stock falls on plans to drop oral Factor D inhibitor (NASDAQ:BCRX)
BioCryst Pharmaceuticals (BCRX) shed ~8% pre-market Thursday on a decision to discontinue BCX9930, an oral inhibitor of Factor D at complement-mediated diseases. Read the full story here.
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new...
Bad flu season turned even worse around Thanksgiving - CDC
A flu season that began early and severe in October has become even worse, with the CDC reporting an uptick in cases the week of Thanksgiving.media briefing, CDC...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst to Present at JMP Securities Hematology & Oncology Summit
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Pharmaceuticals (BCRX) Shares Cross Above 200 DMA
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry...
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
Noteworthy Tuesday Option Activity: SOI, BCRX, SMCI
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2022.